Review examines GLP-1 agonists in diabetic lower extremity artery disease
Authors say real-world signals on amputation risk and wound healing are encouraging but the evidence base and mechanisms remain limited.
PR
By Priya Raman · Science Reporter
Sep 21 20:00 ETSource: British journal of hospital medicine (London, England : 2005)
The wire
- 01A narrative review in the British Journal of Hospital Medicine surveys epidemiology, vascular protection mechanisms and real-world evidence for GLP-1 receptor agonists in diabetic lower extremity peripheral artery disease.
- 02Limb salvage rates stay suboptimal after revascularization, so clinicians managing diabetic PAD are watching whether incretin therapy improves microvascular perfusion and wound healing.
- 03This is a review, not new data; the authors call the clinical evidence base limited and the protective mechanisms incompletely defined.
From the source
Read at pubmed.ncbi.nlm.nih.govGLP-1 Receptor Agonists in Diabetic Lower Extremity Peripheral Artery Disease: From Mechanisms to Clinical Practice
British journal of hospital medicine (London, England : 2005) · 2026 Sep 22 · Pan J, Guo C, Huang Q et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42812078/
